10 Best Performing Healthcare Stocks So Far in 2025

3. SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

YTD Performance: 58.95%

Number of Hedge Fund Holders: 36

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) is a commercial-stage biopharmaceutical company focusing on cancer and severe rare diseases. OGSIVEO (nirogacestat) is its FDA-approved therapy for treating progressing desmoid tumors in the US. The company also has a diversified targeted therapy pipeline covering hematological cancers and solid tumors, with programs ranging from preclinical development to advanced clinical trials.

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) reported $61.5 million in net product revenue for fiscal Q4 2024 and $172.0 million for the entire year in its preliminary results. The company also has $461.9 million in total preliminary cash, cash equivalents, and marketable securities as of December 31, 2024. Management expects its cash position to fund operations through profitability, which the company intends to attain in the first half of 2026.

OGSIVEO is driving the company’s growth, with robust demand from both new and existing patients. SpringWorks Therapeutics, Inc.’s (NASDAQ:SWTX) market research shows that it has only reached a small portion of people with desmoid tumors who can potentially benefit from OGSIVEO, reflecting significant potential in the domain.

On February 11, Reuters reported that Merck, the German healthcare group, and SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) are in advanced talks for a potential merger. However, no legally binding agreement has been signed between the two companies yet, and there is no certainty that the acquisition will materialize.